Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours.

Murad MelhemEva HanzeSharon LuOskar AlskärSandra VisserYash Gandhi

Published in: British journal of clinical pharmacology (2022)

Dostarlimab PK parameters are similar to other anti-programmed cell death protein-1 antibodies. The clinical impact of covariates on exposure was limited-to-moderate, supporting recommended dostarlimab monotherapy therapeutic dosing.

Keyphrases

monoclonal antibody
protein protein
amino acid
binding protein
high intensity
combination therapy
open label
small molecule
double blind